Target intelligence / Profile preview

D-alanyl-D-alanine terminus of Lipid II (D-Ala-D-Ala) (D-Ala-D-Ala)

Target
D-Ala-D-Ala
Molecular classification
Bacterial cell wall precursor, Other
01

Overview

The D-alanyl-D-alanine (D-Ala-D-Ala) terminus of the Lipid II peptidoglycan precursor is a critical structural motif in the biosynthesis of the bacterial cell wall (Source: PubChem CID 16219615). Lipid II is a membrane-anchored intermediate that transports peptidoglycan subunits across the cytoplasmic membrane to the site of cell wall assembly (Source: Nature Reviews Microbiology, 2008). The D-Ala-D-Ala dipeptide at the end of the pentapeptide chain serves as the substrate for transpeptidase enzymes, also known as penicillin-binding proteins, which catalyze the cross-linking of the peptidoglycan layer (Source: PMC2823315). This cross-linking provides essential structural integrity and osmotic protection to the bacterium. This specific terminus is the primary molecular target for glycopeptide antibiotics, including vancomycin and teicoplanin (Source: StatPearls, NBK459358). These drugs bind to the D-Ala-D-Ala motif through a network of hydrogen bonds, effectively capping the precursor and sterically hindering the transglycosylation and transpeptidation reactions required for cell wall polymerization. Consequently, the bacterial cell wall cannot be properly formed, leading to cell lysis and death. Clinical resistance often arises when bacteria modify this target to D-alanyl-D-lactate (D-Ala-D-Lac), which drastically reduces antibiotic binding affinity (Source: PubMed, 11544343).

Other names
D-alanyl-D-alanineLipid II pentapeptide terminusPeptidoglycan precursor terminusD-Ala-D-Ala dipeptide
02

Mechanism of action

Binding to the D-Ala-D-Ala terminus of the peptidoglycan precursor Lipid II, thereby sterically inhibiting the transglycosylation and transpeptidation steps of cell wall synthesis (Source: StatPearls, NBK459358).

03

Biological functions

Cell wall biosynthesisPeptidoglycan cross-linkingBacterial cell wall assemblyOther
04

Disease associations

Infection
05

Safety considerations

NephrotoxicityOtotoxicityInfusion-related reactions (Red Man Syndrome)Development of glycopeptide-resistant Enterococci (VRE)
06

Interacting drugs

Vancomycin

4 more in the full profile.

07

Biomarkers

Minimum Inhibitory Concentration (MIC)vanA genotypevanB genotype

Beyond the preview

Go deeper on D-alanyl-D-alanine terminus of Lipid II (D-Ala-D-Ala) (D-Ala-D-Ala).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on D-alanyl-D-alanine terminus of Lipid II (D-Ala-D-Ala) (D-Ala-D-Ala).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call